We know that chronic inflammatory diseases (including PD) are very long lasting, therefore, an adequate period of treatment is required to stop the course of the disease and for progressive reabsorption of the plaque
No published research demonstrates superior outcomes from twice-daily versus once-daily Dihexa administration, and the compounds mechanism suggests more frequent dosing wouldnt necessarily enhance effects
Reducing Chronic Inflammation: Chronic inflammation can stall healing
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease Klaus Kannengiesser1, Christian Maaser, Jan Heidemann, Andreas Luegering, Matthias Ross, Thomas Brzoska, Markus Bohm, Thomas A Luger, Wolfram Domschke, Torsten Kucharzik ~ Review: Int J Mol Sci
Coatings releasing this peptide were reported in laboratory studies to potentially reduce fibrotic capsule thickness around implanted devices